[1] Pere Ginés, Quintero E, Arroyo V, et al. Compensated cirrhosis: Natural history and prognostic factors. Hepatology 1987; 7:122-128.
[2] Solà E, Watson H, Graupera I, et al. Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. Journal of Hepatology 2012; 57:1199-1206.
[3] Yu C, Sharma N, Saab S. Hyponatremia: clinical associations, prognosis, and treatment in cirrhosis. Experimental & Clinical Transplantation 2013; 11:3-11.
[4] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology 2010; 53:397–417
[5] Leiva JG, Salgado JM, Estradas J, et al. Pathophysiology of ascites and dilutional hyponatremia: Contemporary use of aquaretic agents. Annals of Hepatology 2007; 6:214.
[6] Salerno F, Calogero Cammà, Enea M, et al. Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. Gastroenterology 2007; 133:825-834.
[7] Josiassen RC, Curtis J, Filmyer DM, et al. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders. Expert Opinion on Pharmacotherapy 2010; 11:637-648.
[8] Schrier RW, Gross P, Gheorghiade M, et al. SALT Investigators.Tolvaptan, a selective oral vasopressin V2- receptor antagonist, for hyponatremia. New England Journal of Medicine 2006; 355:2099-112.
[9] Matsuzaki M, Hori M, Izumi T, et al. Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study). Cardiovascular Drugs and Therapy 2011; 25:33-45.
[10] Decaux G, Soupart A. Treatment of symptomatic hyponatremia. American Journal of the Medical Sciences 2003; 326: 25-30.
[11] Dahl E, Gluud L L, Kimer N, et al. Meta-analysis: The safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Alimentary Pharmacology & Therapeutics 2012; 36:619-626.
[12] Yan L, Xie F, Lu J, et al. The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterology 2015; 15: 65(2015).
[13] Bellos I, Kontzoglou K, Psyrri A, et al. Tolvaptan Response Improves Overall Survival in Patients with Refractory Ascites: A Meta-Analysis. Dig Dis 2019; doi: 10.1159/000503559
[14] Guo H, Wu LJ, Jin Z, et al. Vasopressin V2-receptor antagonist tolvaptan for treating cirrhosis patients with hyponatremia and hepatic edema: A systemic review (in Chinese). World Chinese Journal of Digestology 2016; 24:938-946
[15] Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. [http://handbook.cochrane. org]. Published March 15, 2011. Accessed August 15, 2019.
[16] Andrés Cárdenas, Pere Ginès, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology 2012; 56:571-578.
[17] Isao Sakaida, Seiji Kawazoe, Kozo Kajimura, et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatology Research 2014; 44:73-82.
[18] Kiwamu Okita, Seiji Kawazoe, Chitomi Hasebe, et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial. Hepatology Research 2014; 44:83-91.
[19] Haruki Uojima, Hisashi Hidaka, Tsuyoshi Nakayama, et al. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World Journal of Gastroenterology 2017; 23:8062-8072.
[20] Yong Feng Wang, Jie Ting Tang, Tao Han, et al. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial Journal of Digestive Diseases. 2018; 19:144-154.
[21] Wang Shuzhen, Zhang Xin, Han Tao, et al. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterology 2018; 18:137.
[22] Umemura T, Shibata S, Sekiguchi T, et al. Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis. Hepatology Research 2015; 45:739-744.
[23] Kogiso T, Kobayashi M, Yamamoto K, et al. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan. Internal Medicine 2017; 56:2993-3001.
[24] Heuman D M. Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List. New England Journal of Medicine 2008; 359:1018-1026.
[25] Chen RP, Zhu Ge XJ, Huang ZM, et al. Prophylactic Use of Transjugular Intrahepatic Portosystemic Shunt Aids in the Treatment of Refractory Ascites. Journal of Clinical Gastroenterology 2014; 48:290-299.
[26] Bhogal HK, Sanyal AJ. Using Transjugular Intrahepatic Portosystemic Shunts for Complications of Cirrhosis. Clinical Gastroenterology and Hepatology 2011; 9:936-946.